1. The identification of three novel biomarkers of major adverse kidney events.
- Author
-
Haase M, Bellomo R, Albert C, Vanpoucke G, Thomas G, Laroy W, Verleysen K, Kropf S, Kuppe H, Hetzer R, and Haase-Fielitz A
- Subjects
- Acute Kidney Injury blood, Acute Kidney Injury urine, Acute-Phase Proteins urine, Aged, Aged, 80 and over, Biomarkers blood, Biomarkers urine, Cathepsin L blood, Cathepsin L urine, Female, Humans, Lipocalin-2, Lipocalins blood, Lipocalins urine, Male, Proto-Oncogene Proteins blood, Proto-Oncogene Proteins urine, Acute Kidney Injury diagnosis, Cystatin C blood, Cystatin C urine, Heparan Sulfate Proteoglycans blood, Heparan Sulfate Proteoglycans urine, Latent TGF-beta Binding Proteins blood, Latent TGF-beta Binding Proteins urine
- Abstract
Aim: To describe the prognostic value of three novel biomarkers for acute adverse kidney events compared with routine biological markers., Material & Methods: We used high-end MS to quantify biomarkers predictive of acute kidney injury (AKI) and major adverse kidney events (MAKE) in 100 adult patients after open heart surgery (n = 100)., Results: Early postoperatively measured LG3 (a C-terminal fragment of perlecan), LTBP2 (latent transforming growth factor binding protein-2), Cathepsin L as well as two other renal biomarkers (NGAL, Cystatin C) had greater predictive value for AKI (n = 23) and MAKE (n = 24) compared with creatinine, urea and urine output., Conclusions: LG3, LTBP2 and Cathepsin L deserve further exploration as biomarkers for the early identification of patients at risk of MAKE.
- Published
- 2014
- Full Text
- View/download PDF